The insulin-like growth factor 1 receptor in cancer: old focus, new future.
The importance of insulin-like growth factor 1 receptor (IGF-1R) signalling in malignant behaviour of tumour cells is well established. Currently, development of drugs targeting the IGF-1R as anticancer treatment is emerging. Several IGF-1R targeting strategies are being investigated in phases I and II clinical trials. Interactions of IGF-1R with insulin receptor, however, might complicate efficiency and tolerability of such drugs. This review describes mechanisms, recent developments and potential limitations of IGF-1R antibodies and tyrosine kinase inhibitors.
Hartog
Hermien
H
Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Wesseling
Jelle
J
Boezen
H Marike
HM
van der Graaf
Winette T A
WT
D000970:Antineoplastic Agents / Q000494:pharmacology*; D005544:Forecasting; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D017526:Receptor, IGF Type 1 / Q000187:drug effects / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D017526:Receptor, IGF Type 1